Platelet Aggregation Studies and Coagulation Profile in Sickle Cell Disease in Symptomatic and Steady State Patients

Vaishali B Nagose; Purnima M Kodate; Dinkar T Kumbhalkar; Shivanand S Rathod; Suprita P Nayak

doi:10.1007/s12288-023-01703-9

Platelet Aggregation Studies and Coagulation Profile in Sickle Cell Disease in Symptomatic and Steady State Patients

Indian J Hematol Blood Transfus. 2024 Apr;40(2):281-288. doi: 10.1007/s12288-023-01703-9. Epub 2023 Oct 18.

Authors

Vaishali B Nagose^{1

2}, Purnima M Kodate¹, Dinkar T Kumbhalkar¹, Shivanand S Rathod³, Suprita P Nayak¹

Affiliations

¹ Department of Pathology, Government Medical College and Hospital, Nagpur, India.
² Department of Pathology, Government Medical College, Sindhudurg, India.
³ Department of Physiology, Dr Ulhas Patil Medical College and Hospital, Nagpur, India.

PMID: 38708151
PMCID: PMC11065820 (available on 2025-04-01)
DOI: 10.1007/s12288-023-01703-9

Abstract

To determine whether there is higher degree of platelet and/ or coagulation activation in sickle cell anaemia (SS) patients in complications and with clinical risk factors. A cross sectional study was conducted at a tertiary health care centre in central India with study groups: sickle cell disease (SCD): sickle cell anaemia (SS) and sickle cell trait (AS) consisting of 100 subjects each and controls (AA) with 40 subjects. Platelet aggregation (PA) with ADP, collagen and epinephrine, PT and aPTT were performed in all subjects and PA with ristocetin in ten candidates of each group. ANOVA and student's unpaired t test were used to compare PA and coagulation profile of the three groups with respect to age groups, gender, present diagnosis, history of complications, frequency of hospital admissions (high ≥ 3/year) and frequency of blood transfusion (high > 2/year). The max PA% with ADP was significantly less in SS patients in steady state, which was even lesser in those having symptoms, complications in past/ present, high-frequency hospital admission and > 2 blood transfusions per year subgroups, as compared to all other groups and subgroups, but not consistently with collagen and epinephrine. The max PA % with ristocetin was least in SS with complications. No statistically significant difference in PT and aPTT values among the various clinical risk subgroups and groups was found. SCD patients can be monitored by using PA with ADP for their timely and better management. PA with ADP, PT and aPTT should be added to the workup of these patients for improved prognostication.

Keywords: Adenosine diphosphate (ADP); Collagen; Platelet activation; Platelet aggregation (PA); Sickle cell anaemia (SS).

© The Author(s), under exclusive licence to Indian Society of Hematology and Blood Transfusion 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.